Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
Tarsus Pharmaceuticals (NASDAQ: TARS) has announced it will host a live webcast on Thursday, August 8, 2024, at 1:30 p.m. PT / 4:30 p.m. ET to report its second quarter 2024 financial results and provide a corporate update. The company, focused on addressing unmet needs in eye care through proven science and new technology, will make the webcast accessible to participants via a provided link. A recorded version of the call will be available on the website shortly after the webcast concludes and will remain archived for approximately 90 days.
Tarsus Pharmaceuticals (NASDAQ: TARS) ha annunciato che ospiterà un webcast dal vivo giovedì 8 agosto 2024 alle 13:30 PT / 16:30 ET per riportare i suoi risultati finanziari del secondo trimestre 2024 e fornire un aggiornamento aziendale. L'azienda, focalizzata nel soddisfare esigenze insoddisfatte nella cura degli occhi attraverso la scienza comprovata e nuove tecnologie, renderà il webcast accessibile ai partecipanti tramite un link fornito. Una versione registrata della chiamata sarà disponibile sul sito web poco dopo la conclusione del webcast e rimarrà archiviata per circa 90 giorni.
Tarsus Pharmaceuticals (NASDAQ: TARS) ha anunciado que realizará un webcast en vivo el jueves 8 de agosto de 2024 a las 1:30 p.m. PT / 4:30 p.m. ET para informar sobre sus resultados financieros del segundo trimestre de 2024 y proporcionar una actualización corporativa. La compañía, centrada en abordar necesidades no satisfechas en el cuidado de los ojos a través de ciencia probada y nuevas tecnologías, hará que el webcast sea accesible para los participantes a través de un enlace proporcionado. Una versión grabada de la llamada estará disponible en el sitio web poco después de que finalice el webcast y permanecerá archivada durante aproximadamente 90 días.
타르수스 제약(Tarsus Pharmaceuticals, NASDAQ: TARS)은 2024년 8월 8일 목요일 오후 1시 30분 PT / 4시 30분 ET에 2024년 2분기 재무 결과를 보고하고 기업 업데이트를 제공하기 위해 라이브 웹캐스트를 개최한다고 발표했습니다. 과학적인 접근과 새로운 기술을 통해 눈 건강 분야의 미충족 수요를 해결하는 데 집중하는 이 회사는 제공된 링크를 통해 참여자들이 웹캐스트에 접근할 수 있도록 할 것입니다. 웹캐스트가 종료된 후 웹사이트에 호출 내용의 녹음본이 곧바로 제공되며, 약 90일간 아카이브로 유지됩니다.
Tarsus Pharmaceuticals (NASDAQ: TARS) a annoncé qu'elle organisera un webcast en direct le jeudi 8 août 2024 à 13h30 PT / 16h30 ET pour faire état de ses résultats financiers du deuxième trimestre 2024 et fournir une mise à jour de l'entreprise. L'entreprise, axée sur la satisfaction des besoins non comblés en matière de soins oculaires grâce à la science éprouvée et aux nouvelles technologies, rendra le webcast accessibles aux participants via un lien fourni. Une version enregistrée de l'appel sera disponible sur le site Web peu après la fin du webcast et restera archivée pendant environ 90 jours.
Tarsus Pharmaceuticals (NASDAQ: TARS) hat angekündigt, dass am Donnerstag, den 8. August 2024, um 13:30 Uhr PT / 16:30 Uhr ET ein Live-Webcast stattfinden wird, um die Finanzergebnisse des zweiten Quartals 2024 zu berichten und ein Unternehmensupdate zu geben. Das Unternehmen, das sich darauf konzentriert, unerfüllte Bedürfnisse im Bereich der Augenheilkunde durch bewährte Wissenschaft und neue Technologien zu adressieren, wird den Webcast über einen bereitgestellten Link für Teilnehmer zugänglich machen. Eine aufgezeichnete Version des Calls wird kurz nach Abschluss des Webcasts auf der Website verfügbar sein und etwa 90 Tage lang archiviert bleiben.
- None.
- None.
IRVINE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, August 8, 2024 to report its second quarter 2024 financial results and provide a corporate update.
Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology and infectious disease prevention. XDEMVY® (lotilaner ophthalmic solution)
Media Contact:
Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
akemp@tarsusrx.com
Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com
FAQ
When will Tarsus Pharmaceuticals (TARS) report its Q2 2024 financial results?
How can investors access Tarsus Pharmaceuticals' (TARS) Q2 2024 earnings webcast?
Will there be a replay available for Tarsus Pharmaceuticals' (TARS) Q2 2024 earnings call?
